SOT 사이트에 제공되어 있는 Eminent Toxicologist Lecture Series 입니다. 출처: SOT (Society of Toxicology) http://www.toxicology.org/education/edu/eminent.asp   In this lecture SOT Past President John Doull, MD, PhD, FAACT, ATS, presents his unique perspective as a charter member of SOT who was instrumental in the maturation of the discipline and of the Society. He describes how toxicology became an academic discipline with the vision of key individuals, the formation of academic programs, development of a textbook, and creation of journals dedicated to the discipline. This lecture was a seminar recorded at the University of Kansas Medical Center December 13, 2011.   John Doull Biography John Doull, MD, PhD, FAACT, ATS, is Professor Emeritus of Pharmacology and Toxicology at the University of Kansas Medical School. A charter member of SOT, he was 1986–1987 President and has received numerous awards in recognition of his important and extensive contributions to toxicology. Among the SOT awards are the Merit Award (1993), the Founders Award (2008), and the John Doull Award (1992). He has also received the ATS Mildred Christian Achievement Award (2013), the Samuel Kuna Award (1989) from Rutgers University/Robert Wood Johnson Medical School, the International Achievement Award (1990) from the International Society for Regulatory Toxicology and Pharmacology, the Commanders Award for Public Service (1990) from the Department of the Army, the Distinguished Medical Alumnus Award (1992) from the University of Chicago, the Stockinger Award (1990)from the American Conference of Governmental Industrial Hygienists, the Founder's Award from CIIT (1996), the Meritorious Service Award from ACGIH, and the Distinguished Service Award from the American College of Toxicology. The founding co-­editor of Casarett and Doull’s Toxicology: The Basic Science of Poisons, he has served on scientific advisory boards for Congress, the White House, NRC, NIH, EPA, NIOSH, and many others and consults with many organizations. He is a national associate of the National Academies.  

SOT 사이트에 제공되어 있는 Eminent Toxicologist Lecture Series 입니다. 발표자료는 아래 파일로 첨부되어 있습니다. 출처: SOT (Society of Toxicology) http://www.toxicology.org/education/edu/eminent.asp   SOT Past President Curt Klaassen, PhD, DABT, ATS, shares his career-spanning search of the answer to “How do we adapt to chemicals?” He covers the emergence of the field of toxicology to present discoveries. The lecture culminates with the major discovery of the Nrf2 pathway’s critical importance to toxicology, its modulation by plant-based compounds, its interactions with numerous genes and its potential as a therapeutic target.   Curtis D. Klaassen Biography Curtis D. Klaassen, PhD, DABT, ATS, was a Distinguished Professor at the University of Kansas Medical Center and was instrumental in establishing his department as one of the top departments for research and training in toxicology in the world. Dr. Klaassen’s research interests have centered on how we adapt to chemicals in the environment. His studies have included the hepatobiliary disposition of xenobiotics, the toxicity of cadmium, the hepatotoxicity of chemicals, and mechanisms of chemical-induced thyroid tumors. Dr. Klaassen is editor of Casarett and Doull’s Toxicology: The Basic Science of Poisons, considered the premier textbook in the field. He has twice been named a “Highly Cited Researcher” (2002, 2007) by the Institute for Scientific Information, a designation held by less than one half of one percent of all researchers. He has been elected to 27 different positions in professional organizations, including President of SOT from 1990–1991 and President of IUTOX 1992–1995. An SOT member since 1969, his Society recognition includes the Achievement Award, Merit Award, Education Award, the Burroughs Welcome Toxicology Scholar Award, the Women in Toxicology Mentoring Award, and numerous Regional Chapter and Specialty Section awards.  

SOT 사이트에 제공되어 있는 Eminent Toxicologist Lecture Series 입니다. 발표자료는 아래 파일로 첨부되어 있습니다. 출처: SOT (Society of Toxicology) http://www.toxicology.org/education/edu/eminent.asp Melvin E. Andersen—“45 Years Modeling Dose-Response Relationships: An Unanticipated Career!”   This lecture examines my experience using quantitative models for understanding dose-response relationships, as well as touching on pharmacokinetics, pharmacodynamics, and new directions in cell pathway based models. Instead of postdoctoral work on shark hemoglobin, military service directed me to assess the toxicity of chemicals found onboard nuclear submarines. Training in modeling small and large molecule kinetics led me to question why probit analyses were used for dose response, why the logarithm of inhaled concentration is a measure of dose, and what is the relationship expected between inhaled concentration and chemical in tissue or between the amount of chemical and response? The main lessons of a long career are that models require us to state our ideas clearly and quantitatively and then to see if our ideas are correct or in need of revision. The use of these models repeatedly shows that it is even more important to know our ideas are wrong than simply to think they might be right.   Melvin E. Andersen Biography Melvin Andersen, PhD, DABT, CIH, ATS, is Distinguished Research Fellow at ScitoVation LLC, Research Triangle Park, North Carolina. Previously, he was at The Hamner Institutes for Health Sciences. Over a 45-year career, he worked in government (US Navy, DoD, US EPA), industry (Chemical Industry Institute of Toxicology), academia (Colorado State University), and consulting (ICF Kaiser Consulting). Dr. Andersen introduced physiologically-based pharmacokinetic (PBPK) modeling. Other long-term interests include biologically realistic models of the uptake, distribution, metabolism, and biological effects of drugs and toxic chemicals and applying these models in safety assessments and quantitative health risk assessments. Dr. Andersen has mentored 13 graduate students and 13 postdoctoral researchers and served on an additional 11 graduate student research committees. He has served on or chaired many regulatory review panels, both domestic and international, regarding chemicals of environmental interest, including contributing to the 2007 National Academy of Sciences report “Toxicity Testing in the 21st Century: A Vision and a Strategy.” Author/co-author of 400 peer reviewed publications, 70 book chapters, and 30 technical reports, his work has more than 18,000 citations. He has received numerous SOT awards including the Frank Blood, Achievement, Arnold J. Lehman, Best Paper of the Year in Toxicological Sciences, and Merit.  

SOT (Society of Toxicology) 사이트에 제공되어 있는 강연 자료를 올려드립니다. 출처: http://www.toxicology.org/education/pw/lectures.asp Biomarkers of Disease and Toxicity: Exploiting the Interconnections—2013 Chairperson(s): Donna L. Mendrick, US FDA, Division of Systems Biology, Jefferson, AR, and William B. Mattes, PharmPoint Consulting, Poolesville, MD. With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b) translational biomarkers that may link animal and in vitro model observations with clinical reality, there is a need to broaden the understanding of how experimental models may replicate human toxicity and disease processes. Multicellular organisms may have large numbers of genes and proteins, but a relatively limited repertoire in terms of pathophysiology in response to disease or toxicant exposure. This fact allows research to improve and protect human health to be founded on the use of model systems that allow for tractable experimentation. Animal models and, more recently, in vitro systems have served as a means of both exploring mechanisms and identifying hazards in terms of disease and adverse events. However, the interconnections between disease and toxicity are rarely explored leaving the information in silos. This symposium will examine organ-based toxicity and disease processes, and compare lessons learned in biomarker identification and use across toxicity, disease, and species.     Links Between Neurological Disease and Toxicity Presenter: David Gerhold Neurological damage may be caused by environmental agents; MPTP serves as an example, where it, as a contaminant in drugs, let users to develop Parkinson-like symptoms. Indeed nervous system toxicities and disease share common modes and pathways, and the combined use of models of neurological damage caused by drugs, toxicants, and disease may move the field forward faster in the identification and use of translational biomarkers.

SOT (Society of Toxicology) 사이트에 제공되어 있는 강연 자료를 올려드립니다. 출처: http://www.toxicology.org/education/pw/lectures.asp Biomarkers of Disease and Toxicity: Exploiting the Interconnections—2013 Chairperson(s): Donna L. Mendrick, US FDA, Division of Systems Biology, Jefferson, AR, and William B. Mattes, PharmPoint Consulting, Poolesville, MD. With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b) translational biomarkers that may link animal and in vitro model observations with clinical reality, there is a need to broaden the understanding of how experimental models may replicate human toxicity and disease processes. Multicellular organisms may have large numbers of genes and proteins, but a relatively limited repertoire in terms of pathophysiology in response to disease or toxicant exposure. This fact allows research to improve and protect human health to be founded on the use of model systems that allow for tractable experimentation. Animal models and, more recently, in vitro systems have served as a means of both exploring mechanisms and identifying hazards in terms of disease and adverse events. However, the interconnections between disease and toxicity are rarely explored leaving the information in silos. This symposium will examine organ-based toxicity and disease processes, and compare lessons learned in biomarker identification and use across toxicity, disease, and species.     Cardiac Disease, Cardiotoxicity, and Translational Biomarkers Presenter: James R. Turk Heart disease is the leading cause of death in the United States, and myocardial damage from ischemia or cardiotoxic drugs may be followed with biomarkers such as the troponins, natriuretic peptides, and their combination in panels with multiple evolving biomarkers. These tools facilitate an understanding of the parallels between toxicity and background disease in animal models and human heart disease.

SOT (Society of Toxicology) 사이트에 제공되어 있는 강연 자료를 올려드립니다. 출처: http://www.toxicology.org/education/pw/lectures.asp Biomarkers of Disease and Toxicity: Exploiting the Interconnections—2013 Chairperson(s): Donna L. Mendrick, US FDA, Division of Systems Biology, Jefferson, AR, and William B. Mattes, PharmPoint Consulting, Poolesville, MD. With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b) translational biomarkers that may link animal and in vitro model observations with clinical reality, there is a need to broaden the understanding of how experimental models may replicate human toxicity and disease processes. Multicellular organisms may have large numbers of genes and proteins, but a relatively limited repertoire in terms of pathophysiology in response to disease or toxicant exposure. This fact allows research to improve and protect human health to be founded on the use of model systems that allow for tractable experimentation. Animal models and, more recently, in vitro systems have served as a means of both exploring mechanisms and identifying hazards in terms of disease and adverse events. However, the interconnections between disease and toxicity are rarely explored leaving the information in silos. This symposium will examine organ-based toxicity and disease processes, and compare lessons learned in biomarker identification and use across toxicity, disease, and species.      Fibrinogen: A New Kid on the Block of Translational Biomarkers for Kidney Damage Presenter: Vishal S. Vaidya Acute kidney injury (AKI) is a serious public health concern, especially due to the lack of early biomarkers of injury. We provide evidence that fibrinogen may function as a key molecular link between tubulo-vascular damage and regeneration in the kidney and provides new opportunities for its use in the diagnosis and prevention of kidney disease.

SOT (Society of Toxicology) 사이트에 제공되어 있는 강연 자료를 올려드립니다. 출처: http://www.toxicology.org/education/pw/lectures.asp Biomarkers of Disease and Toxicity: Exploiting the Interconnections—2013 Chairperson(s): Donna L. Mendrick, US FDA, Division of Systems Biology, Jefferson, AR, and William B. Mattes, PharmPoint Consulting, Poolesville, MD. With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b) translational biomarkers that may link animal and in vitro model observations with clinical reality, there is a need to broaden the understanding of how experimental models may replicate human toxicity and disease processes. Multicellular organisms may have large numbers of genes and proteins, but a relatively limited repertoire in terms of pathophysiology in response to disease or toxicant exposure. This fact allows research to improve and protect human health to be founded on the use of model systems that allow for tractable experimentation. Animal models and, more recently, in vitro systems have served as a means of both exploring mechanisms and identifying hazards in terms of disease and adverse events. However, the interconnections between disease and toxicity are rarely explored leaving the information in silos. This symposium will examine organ-based toxicity and disease processes, and compare lessons learned in biomarker identification and use across toxicity, disease, and species.   Use of Biomarkers in Hepatology, Liver Disease, and Liver Toxicity   Presenter: Arie Regev Biomarkers are often used in clinical hepatology to detect the presence of a liver disease, distinguish among different types of liver disorders, assess the extent and severity of liver damage, and follow response to treatment. This presentation discusses these biomarkers and their inability to distinguish drug-induced liver injury (DILI) from other causes of hepatic damage and disease.   SOT2013 Use of Biomarkers in Hepatology, Liver Disease, and Liver Toxicity from Society of Toxicology on Vimeo.

SOT (Society of Toxicology) 사이트에 제공되어 있는 강연 자료를 올려드립니다. 출처: http://www.toxicology.org/education/pw/lectures.asp Biomarkers of Disease and Toxicity: Exploiting the Interconnections—2013 Chairperson(s): Donna L. Mendrick, US FDA, Division of Systems Biology, Jefferson, AR, and William B. Mattes, PharmPoint Consulting, Poolesville, MD. With the recent focus on (a) cellular pathways involved in toxicity sequelae and (b) translational biomarkers that may link animal and in vitro model observations with clinical reality, there is a need to broaden the understanding of how experimental models may replicate human toxicity and disease processes. Multicellular organisms may have large numbers of genes and proteins, but a relatively limited repertoire in terms of pathophysiology in response to disease or toxicant exposure. This fact allows research to improve and protect human health to be founded on the use of model systems that allow for tractable experimentation. Animal models and, more recently, in vitro systems have served as a means of both exploring mechanisms and identifying hazards in terms of disease and adverse events. However, the interconnections between disease and toxicity are rarely explored leaving the information in silos. This symposium will examine organ-based toxicity and disease processes, and compare lessons learned in biomarker identification and use across toxicity, disease, and species.   Introduction Presenter: Donna L. Mendrick The usefulness of biomarkers that translate between in vitro/in vivo environments, across species and are shared by disease and toxicity is introduced, with N-acetyltransferase 2 as an example.  

SOT (Society of Toxicology) 사이트에 제공되어 있는 Toxicology Concepts PPT 파일을 아래 첨부하였습니다. 출처: http://www.toxicology.org/education/edu/educators.asp#intro-pnl-open  

주요 부형제 독성정보 : 자세한 자료가 필요하면 CND로 연락주세요 (asancnd.com)   번호 물질 독성자료가 있는 동물종 1 Acacia Nonhuman primate, rat 2 Acetate buffer Nonhuman primate, minipig, mouse, rat 3 Acetic acid Dog, mouse, rat 4 Acetone Guinea pig, mouse, rabbit, rat 5 Acetonitrile Dog 6 Acetylated lanolin alcochol Minipig 7 Acetylmethylamide Nonhuman primate 8 Alcohol denatured SDA Minipig 9 Alginic acid Rat 10 Anecortave acetate Rat 11 Antifoam 1510-USTM Rat 12 Avicel CL-611TM Dog 13 Balanced salt saline Rabbit 14 Basal salt solution Mouse 15 Benzonic acid Rat 16 Benzyl alcohol Cat, Dog, nonhuman primate, rat 17 β-Cyclodextrin Dog, mouse, nonhuman primate, rat 18 BHA Minipig 19 BHT Cat, Dog, nonhuman primate, rat 20 Bicarbonate buffer Mouse 21 Calcium chloride Mouse 22 Canola oil Dog 23 Capmul MCMTM Nonhuman primate 24 Capmul MCM NFTM Dog, rat 25 Capmul PG 8TM Dog, rat 26 Capryol 90TM Dog, rabbit, rat 27 CaptisolTM Dog, mouse, nonhuman primate, rat 28 Carbomer 974PTM Minipig, mouse 29 Carbopol Ultrez 10TM Minipig 30 Carboxymethylcellulose Dog, minipig, mouse, nonhuman primate, rabbit, rat 31 Carboxymethylcellulose calcium Dog 32 Carboxymethylcellulose sodium Mouse, rabbit, rat 33 CavisolTM Dog, rat 34 Cetostearyl alcohol Minipig 35 Cetyl acetate Minipig 36 Cetyl alcohol Minipig, mouse 37 Citrate buffer Dog, nonhuman primate, rat 38 Citric acid buffer Cat, dog, nonhuman primate, rat 39 Coconut oil Minipig 40 Collagen matrix Nonhuman primate, rabbit 41 Corn oil Chicken embryo, dog, mouse, nonhuman primate, rabbit rat 42 Cottonseed oil Dog 43 Cyclodextrin Rat 44 Cyclohexane Rabbit, rat 45 Cyclomethicone NF Minipig 46 DAM Dog, rat 47 Dextrose Cat, dog, minipig, nonhuman primate, rabbit, rat 48 Dichlorvos Nonhuman primate 49 Diethylacetamide Cat, chicken, dog, mouse, rabbit, rat 50 Diethylene glycolmonoethyl ether Nonhuman primate 51 Dimethicone Rabbit 52 Dimethiconol blend 20 Minipig 53 Dimethylacetamide Chicken, dog, mouse, rabbit, rat 54 Dimethyl sulfoxide Dog, guinea pig, minipig, mouse, nonhuman primate, rabbit, rat 55 Disodium hydrogen phosphate dihydrate Nonhuman primate 56 Docosanol Minipig 57 Dulbecco's modified PBS Rat 58 Dulbecco's PBS Rat 59 EDTA Minipig, nonhuman primate, rat 60 Ethanol Dog, guinea pig, minipig, mouse, nonhuman primate, rat 61 Fumaric acid Dog 62 Gelatin Dog, nonhuman primate, 63 Gelatin phosphate buffer Minipig 64 GelucireTM Minipig 65 Gelucire 44/14TM Dog, minipig, mouse, rabbit, rat 66 Gelucire 50/13TM Rat 67 Gluconic acid Dog, rat 68 Glycerol Dog, guinea pig, minipig, mouse, nonhuman primate, rabbit, rat 69 Glyceryl stearate SE Minipig 70 Glycofurol Dog 71 Glycol dimethacrylate crosspolymer Rat 72 Gum tragacanth Mouse 73 Gum xanthan Minipig, rabbit, rat 74 Hexylene glycol Minipig 75 Histidine Dog, rat 76 Hydrochloric acid Dog, rat 77 Hydrogenated castor oil Minipig 78 Hydroxyethylcellulose Rat 79 Hydroxypropyl β-cyclodextrin Dog, mouse, nonhuman primate, rat 80 Hydroxypropyl cellulouse Minipig, rat 81 Hydroxypropyl methylcellulose Dog, minipig, mouse, nonhuman primate, rat 82 Hydroxypropyl methylcellulose acetate succinate Dog, minipig, mouse, rabbit, rat 83 Hymetellose Rabbit 84 Hypotonic PBS Dog, rat 85 Imwitor 742TM Hamster, nonhuman primate, rat 86 Isopropyl alcohol Dog, rabbit 87 Isopropyl myristate Minipig, mouse, rabbit 88 Isotonic saline Rat 89 KolliphorTM Nonhuman primate 90 Kolliphor ELTM Dog, mouse, nonhuman primate, rat 91 Kolliphor ELPTM Dog 92 Kolliphor HS15TM (see also Solutol HS15) Minipig 93 Kolliphor RH40TM Dog, rat 94 Labrafil M1944TM Dog, rabbit, rat 95 LabrasolTM Dog, minipig, rabbit, rat 96 Lactated Ringer's Nonhuman primate 97 Lactic acid Dog, rat 98 Lactose Dog, nonhuman primate, rat 99 Lanolin Minipig, rabbit 100 Lanolin alcohol NF Minipig 101 L-Arginine HCl USP Minipig, nonhuman primate 102 L-Ascorbic acid Rat 103 Lauroglycol 90TM Rabbit, rat 104 Maltitol solution Rat 105 Maltol Guinea pig, rabbit 106 Mannitol Dog, minipig, mouse, nonhuman primate, rabbit, rat 107 Methanesulfonic acid Rat 108 MethocelTM Nonhuman primat, rat 109 Methyl methacrylate Rat 110 Methylcellulose Dog, guinea pig, mouse, nonhuman primate, rabbit, rat 111 Methylparaben Minipig 112 Methylpyrrolidone Dog, minipig, mouse 113 Mineral oil Cat, dog, guinea pig, minipig, mouse, rat 114 Myristyl alcohol Minipig 115 Neobell 1053 OilTM Mouse, rat 116 Octoxynol-40 Dog, rabbit 117 Oleic acid NF Minipig 118 Oleyl alcohol NF Minipig 119 Olive oil Minipig, rat 120 Ora-PluseTM suspension Rat 121 Panthenol Minipig 122 Peanut oil Dog, rat 123 Peceol Dog, rat 124 PEG 200 Minipig, nonhumand primate, rabbit, rat 125 PEG 300 Cat, dog, guinea pig, mouse, rabbit, rat 126 PEG 400 Dog, guinea pig, minipig, mouse, nonhuman primate, minipig, rabbit, rat 127 PEG 600 Rat 128 PEG 810 Rat 129 PEG 1000 Mouse, rabbit, rat 130 PEG 1500 Rat 131 PEG 1540 Dog, rabbit, rat 132 PEG 4000 Dog, mouse, rabbit, rat 133 PEG 6000 Rabbit, rat 134 PEG 10000 Rat 135 PEG 400000 Rat 136 Petrolatum Rabbit 137 Phenoxyethanol Minipig, mouse 138 Phosal 53 MCTTM Rat 139 Phosphate Nonhuman primate 140 Phosphate buffer Rat 141 Phosphate-buffered saline Dog, minipig, mouse, nonhuman primate, rabbit, rat 142 Polawax Minipig, mouse 143 Poloxamer 124TM Dog, mouse, rat 144 Poloxamer 188TM Dog, minipig, mouse, nonhuman primate, rabbit, rat 145 Polyethylene terephthalate Rat 146 Poly(glycolide-co-DL-lactide) microspheres Dog 147 Polyglyceyl oleate Rabbit, rat 148 Polyvinylpyrrlidone Dog, nonhuman primate, rabbit, rat 149 Potassium chloride Minipig 150 Propylene glycol Dog, minipig, puinea pig, nonhuman primate, mouse, rabbit, rat 151 Propylene glycol dicaprylate/dicaprate Rat 152 Propylparaben Minipig 153 PVP VA 64 Dog, rat 154 RAMEB Nonhuman primate 155 Safflower oil Dog 156 Salicylic acid Minipig 157 Saline(pH adjusted, pH 4.5) Dog, mouse, rabbit, rat 158 Sesame oil Minipig 159 Shea butter Rat 160 Simethicone Dog, mouse, nonhuman primate, rat 161 Sodium acetate trihydrate buffer Mouse, nonhuman primate 162 Sodium chloride Cat, dog minipig, mouse, nonhuman primate, rabbit, rat 163 Sodium citrate Nonhuman primate, rat 164 Sodium dihydrogen phosphate dihydrate Mouse, nonhuman primate 165 Sodium hydroxide Minipig, mouse, nonhuman primate, rat 166 Sodium lauryl sulfate Dog, rat 167 Sodium metabisulfite Mouse, nonhuman primate, rat 168 Sodium methylparaben Minipig, mouse, rat 169 Sodium phosphate buffer Dog, mouse, nonhuman primate, rat 170 Sodium propylparaben Mouse, rat 171 Sodium succinate Dog, mouse rat 172 Sodium sulfite Rabbit 173 Solutol HS15TM(see also Kolliphor HS15TM) Dog, mouse, nonhuman primate, rat 174 Sorbitan tristearate Minipig 175 Sorbitol Dog, nonhuman primate, rat 176 Soybean oil Dog, minipig, rat 177 Squalane NF Minipig 178 Stearic aicd Minipig 179 Steayl alcohol Minipig 180 Sucrose Cat, dog, nonhuman primate, rabbit, rat 181 Sucrose acetate isobutyrate Cat 182 Sulfobutyl ether β-cyclodextrin Mouse 183 Tartaric acid Rabbit, rat 184 Terbinafine HCLTM placebo nail lacquer Pig 185 Tetraglycol Minipig, rat 186 TranscutolTM Cat, dog, guinea pig, minipig, mouse, rabbit, rat 187 Trehalose Dog, rat 188 Tris buffer Minipig, nonhuman primate 189 Trisodium citrate dihydrate Dog, hamster, mouse, rat 190 Tween 20TM Dog, minipig, mouse, nonhuman primate, rat 191 Tween 80TM Dog, guinea pig, hamster,minipig, mouse, nonhuman primate, rabbit, rat 192 Vitamin E Dog, rabbit, rat 193 Vitamin E TPGS Dog, mouse, rabbit, rat 194 Water(Note: only combination formulations expressly listing water in their ingredients are listed here) Dog, guinea pig, minipig, mouse, nonhuman primate, pig, rabbit, rat 195 White wax Minipig 196 Xylitol Nonhuman primate

[ToxLearn] Module 2, Cells and Tissues: Injury and Repair Toxicology tutorial 사이트 주소를 아래 소개하여 드립니다.  오디오 교육 내용이 함께 제공됩니다. https://toxlearn.nlm.nih.gov/Module2.htm

[ToxLearn] Module 1, Introduction to Toxicology and Dose-Response Toxicology tutorial 사이트 주소를 아래 소개하여 드립니다.  오디오 교육 내용이 함께 제공됩니다. https://toxlearn.nlm.nih.gov/Module1.htm  

Workshop on scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products Session 5: Clinical challenges and experience 출처: Youtube, emainfo https://youtu.be/y4zu0dAD-r4?list=PL7K5dNgKnawbK8pvjhuuuZf4CZKhLXpnK Session 5: Clinical challenges and experience (Part 2) 출처: Youtube, emainfo https://youtu.be/NvZ9nXFPJuM?list=PL7K5dNgKnawbK8pvjhuuuZf4CZKhLXpnK

Workshop on scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products Session 4: Non-clinical development 출처: Youtube, emainfo https://youtu.be/j42OEEL1O5A?list=PL7K5dNgKnawbK8pvjhuuuZf4CZKhLXpnK  

Workshop on scientific and regulatory challenges of genetically modified cell-based cancer immunotherapy products Session 3: Product manufacturing and testing 출처: Youtube, emainfo https://youtu.be/F4x1Kbsl3xI?list=PL7K5dNgKnawbK8pvjhuuuZf4CZKhLXpnK